



**Contacts:** Rob Stewart  
Investor Relations  
Tel (949) 480-8300  
[rs@acaciares.com](mailto:rs@acaciares.com)

**Media Contact:** Adam Handelsman  
President & Founder  
SpecOps Communications  
Tel (212) 518-7721  
[Acacia@SpecOpsComm.com](mailto:Acacia@SpecOpsComm.com)

FOR RELEASE  
February 20, 2014

## **ACACIA SUBSIDIARY PARTNERS WITH A LEADING RESEARCH INSTITUTE ON PATENTS RELATING TO CERAMICS AND ASSOCIATED MANUFACTURING PROCESSES FOR MEDICAL DEVICES**

Newport Beach, CA. – (BUSINESS WIRE) February 20, 2014 – Acacia Research Corporation (NASDAQ: ACTG) announced today that an Acacia subsidiary has partnered with a leading research institute to monetize the institute’s patents relating to ceramics and associated manufacturing processes for medical devices. The research institute will share in the royalties Acacia generates from licensing the patents.

“Acacia continues to increase the number of leading patent portfolios in the medical device and life sciences space,” commented Matt Vella, CEO. “Ceramics are utilized in a wide range of medical devices, including orthopedic, dental and ultrasound applications.”

### **ABOUT ACACIA RESEARCH CORPORATION**

Founded in 1993, Acacia Research Corporation (NASDAQ: ACTG) is the industry leader in patent licensing. An intermediary in the patent marketplace, Acacia partners with inventors and patent owners to unlock the financial value in their patented inventions. Acacia bridges the gap between invention and application, facilitating efficiency and delivering monetary rewards to the patent owner.

For more information, visit: [www.acaciaresearch.com](http://www.acaciaresearch.com)

### ***Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995***

*This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements including those of Matt Vella relating to our increasing number of patent portfolios in the medical device & life sciences space, are based upon our current expectations and speak only as of the date hereof. Our ability to continue increasing our patent portfolios in these technology areas, and our actual results may differ*

*materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the rate at which we can effectively source and secure patent rights in the medical device and life sciences fields, the economic slowdown affecting technology companies, the ability to successfully develop licensing programs and attract new business, rapid technological change in relevant markets, changes in demand for current and future intellectual property rights, legislative, regulatory and competitive developments addressing licensing and enforcement of patents and/or intellectual property in general, and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.*